TW201834673A - 包含猴頭菇的益生菌組合物 - Google Patents
包含猴頭菇的益生菌組合物 Download PDFInfo
- Publication number
- TW201834673A TW201834673A TW106133484A TW106133484A TW201834673A TW 201834673 A TW201834673 A TW 201834673A TW 106133484 A TW106133484 A TW 106133484A TW 106133484 A TW106133484 A TW 106133484A TW 201834673 A TW201834673 A TW 201834673A
- Authority
- TW
- Taiwan
- Prior art keywords
- lactobacillus
- probiotic composition
- lactic acid
- acid bacteria
- bifidobacterium
- Prior art date
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 71
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 61
- 240000000588 Hericium erinaceus Species 0.000 title claims description 56
- 235000007328 Hericium erinaceus Nutrition 0.000 title claims description 56
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 112
- 239000000843 powder Substances 0.000 claims abstract description 73
- 241000894006 Bacteria Species 0.000 claims abstract description 58
- 239000000284 extract Substances 0.000 claims abstract description 58
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 56
- 239000004310 lactic acid Substances 0.000 claims abstract description 56
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 38
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 36
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 25
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 25
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 25
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 24
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 23
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 18
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 18
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 18
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 15
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 15
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 11
- 239000003094 microcapsule Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 15
- 235000013399 edible fruits Nutrition 0.000 claims description 14
- 206010010774 Constipation Diseases 0.000 claims description 13
- 241000186000 Bifidobacterium Species 0.000 claims description 12
- 206010012735 Diarrhoea Diseases 0.000 claims description 12
- 208000004998 Abdominal Pain Diseases 0.000 claims description 11
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 244000199866 Lactobacillus casei Species 0.000 claims description 7
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 229940017800 lactobacillus casei Drugs 0.000 claims description 7
- 241000194031 Enterococcus faecium Species 0.000 claims description 6
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 6
- 230000013872 defecation Effects 0.000 claims description 6
- 241000186012 Bifidobacterium breve Species 0.000 claims description 5
- 241000194032 Enterococcus faecalis Species 0.000 claims description 5
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 5
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 5
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 5
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 5
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 5
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 5
- 244000057717 Streptococcus lactis Species 0.000 claims description 5
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 5
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 5
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 5
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 5
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 4
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000012046 mixed solvent Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229910001220 stainless steel Inorganic materials 0.000 description 9
- 239000010935 stainless steel Substances 0.000 description 9
- 230000007413 intestinal health Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 240000006499 Flammulina velutipes Species 0.000 description 6
- 235000016640 Flammulina velutipes Nutrition 0.000 description 6
- 240000000599 Lentinula edodes Species 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000007602 hot air drying Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical class O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 240000007440 Agaricus campestris Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- DMPGFSQMXITJPT-ZCKYJUNOSA-N Erinacine C Chemical compound C([C@@H]1C2=C(CC[C@]2(C)CC[C@@]1(C)[C@H]1O2)C(C)C)C=C(CO)[C@H]1O[C@H]1[C@H]2OC[C@@H](O)[C@@H]1O DMPGFSQMXITJPT-ZCKYJUNOSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000123222 Hericium Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本發明涉及益生菌組合物,其包含乳酸菌粉末、蘑菇提取物及低聚果糖,其中該乳酸菌粉末包含選自於乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌所組成的一群組中的至少一者。
Description
本發明涉及包含猴頭菇的益生菌組合物。
最近,腸道內微生物對人體的身體健康及精神健康帶來的影響眾所周知,正在進行著使腸道內有益微生物的種類多樣化並增加其活性的努力。在這些努力中,最普通且廣泛使用的是益生菌的攝取。益生菌(probiotics)是指對人體、動物體等的健康帶來有益的影響的生菌,其中,通常使用乳桿菌、雙歧桿菌、乳球菌等乳酸菌。但是,這些益生菌不僅根據菌的種類對人體帶來的影響不同,而且存在攝取的益生菌活著到達所需的身體部位,即,活著到達小腸、大腸等的概率低的問題。對此,為了增加益生菌的體內活性及壽命,將作為益生菌的食物的多個有機物,即,益生元與益生菌一同攝取。
一方面,與普通蘑菇相比,猴頭菇具有多種活性多糖,其中,半乳糖木糖葡聚糖和甘露葡糖矽烷由於含有特殊活性多糖體,因而具有卓越的抗腫瘤性。並且,僅在猴頭菇所具有的多糖體的猴頭菇多糖(Hericium Polysaccharide)通過攻擊細菌或病毒或存在缺陷的細胞來強化巨噬細胞或淋巴細胞,以此防止發生大腸癌或胃癌,而且該猴頭菇多糖對各種胃炎均有效。猴頭菇含有非常豐富的僅在幾種藥用蘑菇中存在的慶西素(Oleanolic Acid),因此具有通過保護胃壁來防止發生胃潰瘍和胃炎的效果。尤其,事實表明,猴頭菇具有促進神經細胞增殖因子(Nerve Growth Factor)的生物合成的猴頭菌酮(Hericenone D)和猴頭菌多醇(Erinacine C)。並且公開了其具有優秀的預防和治療老年癡呆的效果。並且,猴頭菇含有的猴頭菌酮和猴頭菌多醇可通過血液來向大腦傳遞,並促進增殖因子的合成,因此可成為有效的治療方法。並且,以大腦內荷爾蒙腎上腺素的四倍的神經細胞
增殖因子的合成可阻止神經細胞(神經元)的消失並促進神經細胞(神經元)的生成,由此也可對成長期兒童或青少年的智慧發育起到很大的作用。尤其,根據猴頭菇所含的鉀、鈣、鎂等無機質進入體內並與酶相互作用後排出的離子化代謝信號,如肽等的低分子物質被細胞攝取後,最終恢復β細胞的功能並分泌出胰島素。即,通過上述一連串的作用可知,其促進胰島素的正常分泌和血糖值的降低可以改善糖尿病,從而也可用作肝功能改善劑。
本發明人在研究生物活性增加的益生菌的過程中,確認當同時攝取特定的多個益生菌與猴頭菇提取物時,能增進腸道健康,並且完成了本發明。
本發明的目的在於,提供生物活性增加的益生菌組合物。
為了實現上述目的,本發明提供益生菌組合物,其包含:乳酸菌粉末、蘑菇提取物及低聚果糖,其中該乳酸菌粉末包含選自於乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌所組成的一群組中的至少一者。
為達上述之目的,本發明提供一種益生菌組合物,其包含:乳酸菌粉末、蘑菇提取物及低聚果糖,該乳酸菌粉末包含選自由乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌組成的組中的乳酸菌。
在本發明之一實施例中,其中該益生菌組合物包含乳酸雙歧桿菌雙微膠囊粉末。
在本發明之一實施例中,其中該嗜酸乳桿菌為嗜酸乳桿菌CBG-C13,其保藏編號為KACC 91980P。
在本發明之一實施例中,其中該鼠李糖乳桿菌為鼠李糖乳桿菌CBG-C14,其保藏編號為KACC 91981P。
在本發明之一實施例中,其中該乳酸菌粉末包含該乳酸雙歧桿菌的雙微膠囊粉末和該乳酸雙歧桿菌的非雙微膠囊,其中該乳酸雙歧桿菌的雙微膠囊粉末與該乳酸雙歧桿菌的非雙微膠囊的
重量比為1:0.5至1.5。
在本發明之一實施例中,其中該益生菌組合物具有便秘的改善能力。
在本發明之一實施例中,其中該益生菌組合物具有腹瀉及腹痛的改善能力。
在本發明之一實施例中,其中該益生菌組合物有助於排便活動。
在本發明之一實施例中,其中該蘑菇提取物為猴頭菇提取物。
在本發明之一實施例中,其中該蘑菇提取物為猴頭菇子實體的提取物。
在本發明之一實施例中,其中該乳酸菌粉末還包含選自於乳酸乳球菌、屎腸球菌、糞腸球菌、嗜熱鏈球菌、兩岐雙岐桿菌、短雙歧桿菌,動物雙歧桿菌乳酸亞種、乾酪乳桿菌、加氏乳桿菌、德氏乳桿菌保加利亞亞種、瑞士乳桿菌、發酵乳桿菌、副乾酪乳桿菌、羅伊氏乳桿菌及唾液乳桿菌所組成的一群組中的至少一者。
本發明的益生菌組合物通過增進腸道健康來改善便秘並改善腹瀉及腹痛,從而使排便順暢。
本發明涉及益生菌組合物,其包含乳酸菌粉末、蘑菇提取物及低聚果糖,其中該乳酸菌粉末包含選自於乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌所組成的一群組中的至少一者。
本發明另涉及便秘改善方法,該便秘改善方法包含使物件攝取包含乳酸菌粉末、蘑菇提取物及低聚果糖的益生菌組合物的步驟,其中該乳酸菌粉末包含選自於乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌所組成的一群組中的至少一者。
本發明另涉及腹瀉及腹痛的改善方法,該腹瀉及腹痛的改善方法包含使物件攝取包含乳酸菌粉末、蘑菇提取物及低聚果糖的益生菌組合物的步驟,其中該乳酸菌粉末包含選自於乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌所組成的一群組中的至少一者。
本發明另涉及益生菌組合物在製備改善便秘的藥物之用途,該益生菌組合物包含乳酸菌粉末、蘑菇提取物及低聚果糖,其中該乳酸菌粉末包含選自於乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌組成的組中的乳酸菌所組成的一群組中的至少一者。
本發明另涉及益生菌組合物在製備改善腹瀉及腹痛的藥物之用途,該益生菌組合物包含乳酸菌粉末、蘑菇提取物及低聚果糖,其中該乳酸菌粉末包含選自於乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌組成的組中的乳酸菌所組成的一群組中的至少一者。
以下,詳細地說明本發明。
本發明的乳酸菌粉末包含選自由乳酸乳球菌(Lactococuus lactis)、屎腸球菌(Enterococcus faecium)、糞腸球菌(faecalis)、嗜熱鏈球菌(Streptococcus thermophilus)、乳酸雙歧桿菌(Bifidobacterium lactis)、長雙歧桿菌(Bifidobacterium longum)、兩岐雙岐桿菌(bifidum)、短雙歧桿菌(breve)、動物雙歧桿菌乳酸亞種(animalis ssp.lactis)、嗜酸乳桿菌(Lactobacillus acidophilus)、乾酪乳桿菌(casei)、加氏乳桿菌(gasseri)、德氏乳桿菌保加利亞亞種(delbrueckii ssp.bulgaricus)、瑞士乳桿菌(helveticus)、發酵乳桿菌(fermentum)、副乾酪乳桿菌(paracasei)、羅伊氏乳桿菌(reuteri)、唾液乳桿菌(salivarius)、植物乳桿菌(Lactobacillus plantarum)及鼠李糖乳桿菌(Lactobacillus rhamnosus)組成的組中的乳酸菌。較佳地,本發明的乳酸菌粉末包含乳酸乳球菌、屎腸球菌、糞腸球菌、嗜熱鏈球菌、乳酸雙歧桿菌、長雙歧桿菌、兩岐雙岐桿菌、短雙歧桿菌、動物雙歧桿菌乳酸亞種、嗜酸乳桿菌、乾酪乳桿菌、加氏乳桿菌、德氏乳桿菌保加利亞亞種、瑞士乳桿菌、發酵乳桿菌、副乾酪乳桿菌、羅伊氏乳
桿菌、唾液乳桿菌、植物乳桿菌及鼠李糖乳桿菌。更佳地,本發明的乳酸菌粉末包含乳酸乳球菌、屎腸球菌、糞腸球菌、嗜熱鏈球菌、乳酸雙歧桿菌、長雙歧桿菌、兩岐雙岐桿菌、短雙歧桿菌、動物雙歧桿菌乳酸亞種、嗜酸乳桿菌、乾酪乳桿菌、加氏乳桿菌、德氏乳桿菌保加利亞亞種、瑞士乳桿菌、發酵乳桿菌、副乾酪乳桿菌、羅伊氏乳桿菌、唾液乳桿菌、植物乳桿菌、鼠李糖乳桿菌及乳酸雙歧桿菌雙微膠囊粉末。
此時,除該乳酸雙歧桿菌雙微膠囊粉末以外的剩餘的多種乳酸菌為非雙微膠囊。非雙微膠囊的該多種乳酸菌能夠以其他膠囊形態塗敷,也可以未被塗敷。
本發明的乳酸菌粉末以1:0.5至1.5的重量比包含乳酸雙歧桿菌雙微膠囊粉末和非雙微膠囊的乳酸雙歧桿菌,較佳地,以1:0.8至1.2的重量比包含乳酸雙歧桿菌雙微膠囊粉末和非雙微膠囊的乳酸雙歧桿菌,更佳地,以1:1的重量比包含乳酸雙歧桿菌雙微膠囊粉末和非雙微膠囊的乳酸雙歧桿菌。
較佳地,該乳酸雙歧桿菌為乳酸雙歧桿菌CBG-C10(保藏編號:KACC 15464或KCTC11978BP)。較佳地,該長雙歧桿菌為長雙歧桿菌CBG-C11(保藏編號:KCTC 11979BP)。該嗜酸乳桿菌為嗜酸乳桿菌CBG-C13(保藏編號:KACC 91980P)。較佳地,該植物乳桿菌為植物乳桿菌JBMI F5(保藏編號:KACC 91638P)。該鼠李糖乳桿菌為鼠李糖乳桿菌CBG-C14(保藏編號:KACC 91981P)。
尤其,較佳地,該本發明的益生菌組合物使用嗜酸乳桿菌CBG-C13(保藏編號:KACC 91980P)及鼠李糖乳桿菌CBG-C14(保藏編號:KACC 91981P)。
並且,韓國授權專利號10-1446309、韓國授權專利號10-1401530及韓國授權專利號10-1274467以及韓國專利申請號10-2015-0023370(即韓國授權專利10-1655851號)及韓國專利申請號10-2015-0023375(即韓國授權專利10-1655852號)的全部內容均包含在本申請的說明書中作為參考。
較佳地,本發明的蘑菇提取物為猴頭菇提取物。更佳地,本
發明的蘑菇提取物為猴頭菇子實體的提取物、猴頭菇菌絲體的提取物或猴頭菇子實體及菌絲體的提取物。較佳地,該提取物為水或碳原子數為5以下的低級乙醇的提取物,更佳選為水或碳原子數為3以下的低級醇的提取物,最佳為乙醇提取物。此時,較佳地,該乙醇提取物為利用包含乙醇和水的溶劑來進行提取的提取物。通過添加該猴頭菇提取物來使本發明的益生菌組合物在生物體內的活性增加。較佳地,當製備本發明的益生菌組合物時,一同使用糊精。此時,以10:15至30重量比混合糊精和猴頭菇提取物,有利於防止因猴頭菇的高粘度而導致的益生菌組合物的聚集現象,並且有利於實現均勻且乾燥的粉末化。
本發明的益生菌組合物使腸道內微生物的種類多樣化,並且增加腸道內有益微生物的活性,而且抑制腸道內有害菌的活性來增進腸道健康。本發明的益生菌組合物對於便秘的人具有改善便秘的功效,對於經常腹瀉及腹痛的人具有通過減少腹瀉及腹痛來改善的功效。即,本發明的益生菌組合物通過增進腸道健康來幫助排便活動。
攝取本發明的益生菌組合物的物件為包含人類的哺乳動物。該物件包含便秘的人、腹瀉及腹痛頻繁的人、經常有腸道問題的人,但不限定於此。
較佳地,本發明的益生菌組合物為粉末形態,可通過如片劑、硬質膠囊劑或軟質膠囊劑、液劑、懸浮劑等口服給藥用製劑的形態來使用,這些製劑可使用可接受的常規的載體,例如,在口服給藥製劑的情況下,可通過使用賦形劑、結合劑、崩解劑、滑潤劑、加溶劑、助懸劑、保鮮劑或增量劑等來配製。
參照詳細後述的實施例,使本發明的優點、特徵及實現這些的方法明確。但是,本發明並不限定於以下揭示的實施例,而是將以互不相同的多種形態體現,並且本實施例僅使本發明的揭示完整,為了向本發明所屬領域普通技術人員完整地說明發明的範疇而提供,本發明僅是通過發明要求保護範圍來定義。
本發明的材料及方法
本發明的多種乳酸菌,選自於下列表1的多種乳酸菌,從科
倍健(chebigen)株式會社購入多種乳酸菌並使用。並且,從科倍健株式會社購入乳酸雙歧桿菌CBG-C10的雙微膠囊粉末(Bifidobacterium lactis)並使用。其中,嗜酸乳桿菌CBG-C13(保藏編號:KACC 91980P)及鼠李糖乳桿菌CBG-C14(保藏編號:KACC 91981P)具有耐酸性、耐膽汁性及抗生素耐藥性,尤其在腸道內有益菌增殖及有害菌抑制方面具有優秀的效果,並且幫助排便活動的能力非常優秀。
本發明的猴頭菇的子實體及菌絲體,購自市面上銷售的韓國產猴頭菇的子實體及菌絲體並使用。本發明的香菇及金針菇,同樣購自市面上銷售的韓國產香菇及金針菇並使用。
本發明的製備例1:製備猴頭菇子實體粉末
在清洗乾淨10kg的猴頭菇子實體後,在圓筒形不銹鋼減壓乾燥機中以40℃至60℃的溫度乾燥20小時以上,來製備水分含量為3%以下的猴頭菇子實體乾燥體。用針磨機(pin mill)粉碎所製備的猴頭菇子實體乾燥體,來製備出約為50目(mesh)的猴頭菇子實體粉末。
本發明的製備例2:製備猴頭菇菌絲體粉末
在清洗乾淨10kg的猴頭菇菌絲體後,在圓筒形不銹鋼減壓乾燥機中以40℃至60℃的溫度乾燥20小時以上,來製備水分含量為3%以下的猴頭菇菌絲體乾燥體。用針磨機粉碎所製備的猴頭菇菌絲體乾燥體,來製備約為50目的猴頭菇菌絲體粉末。
本發明的製備例3:製備猴頭菇提取物A
將5kg的在製備例1中製備的猴頭菇子實體粉末放入2.5L的乙醇和10L的水的混合溶劑後,在設有逆流(reflux)裝置的100L的不銹鋼容器中以90℃至98℃的溫度加熱24小時來進行提取。並且,對上述粗提取物用無紡布篩檢程式來進行過濾之後,以減壓蒸餾方式蒸餾混合溶劑,以此製備500mL的濃縮的液體形態的猴頭菇子實體提取物,並且對其進行熱風乾燥後進行粉碎,從而製備猴頭菇提取物A。
本發明的製備例4:製備猴頭菇提取物B
將5kg的在製備例2中製備的猴頭菇菌絲體粉末放入2.5L的乙醇和10L的水的混合溶劑後,在設有逆流裝置的100L的不銹鋼容器中以90℃至98℃的溫度加熱24小時來進行提取。並且,對上述粗提取物用無紡布篩檢程式來進行過濾之後,以減壓蒸餾方式蒸餾混合溶劑,以此製備500mL的濃縮的液體形態的猴頭菇菌絲體提取物,並且對其進行熱風乾燥後進行粉碎,從而製備猴頭菇提取物B。
本發明的製備例5:製備猴頭菇提取物C
混合3.5kg的在製備例1中製備的猴頭菇子實體粉末和1.5kg的在製備例2中製備的猴頭菇菌絲體粉末來製備猴頭菇粉末混合物。將5kg的上述混合物放入2.5L的乙醇和10L的水的混合溶劑後,在設有逆流裝置的100L的不銹鋼容器中以90℃至98℃的溫度加熱24小時來進行提取。並且,對上述粗提取物用無紡布篩檢程式來進行過濾之後,以減壓蒸餾方式蒸餾混合溶劑,以此製備500mL的濃縮的液體形態的猴頭菇菌絲體及猴頭菇子實體混合物的提取物,並且對其進行熱風乾燥後進行粉碎,從而製備猴頭菇提取物C。
本發明的製備例6:製備香菇提取物粉末
在清洗乾淨10kg的香菇後,在圓筒形不銹鋼減壓乾燥機中以40℃至60℃的溫度乾燥20小時以上,來製備水分含量為3%以下的香菇乾燥體後進行粉碎。將5kg的香菇粉末放入2.5L的乙醇和10L的水的混合溶劑後,在設有逆流裝置的100L的不銹鋼容器中以90℃至98℃的溫度加熱24小時來進行提取。並且,對上述粗提取物用無紡布篩檢程式來進行過濾之後,以減壓蒸餾方式蒸餾混合溶劑,以此製備500mL的濃縮的液體形態的香菇提取物,並且對其進行熱風乾燥後進行粉碎,從而製備香菇提取物粉末。
本發明的製備例7:製備金針菇提取物粉末
在清洗乾淨10kg的金針菇後,在圓筒形不銹鋼減壓乾燥機中以40℃至60℃的溫度乾燥20小時以上,來製備水分含量為3%以下的香菇乾燥體後進行粉碎。將5kg的金針菇粉末放入2.5L的乙醇和10L的水的混合溶劑後,在設有逆流裝置的100L的不銹鋼容器中以90℃至98℃的溫度加熱24小時來進行提取。並且,對上述粗提取物用無紡布篩檢程式來進行過濾之後,以減壓蒸餾方式蒸餾混合溶劑,以此製備500mL的濃縮的液體形態的金針菇提取物,並且對其進行熱風乾燥後進行粉碎,從而製備金針菇提取物粉末。
本發明的實施例1
製備乳酸菌粉末
在100重量份的蒸餾水中,加入10重量份的牛奶並混合後進行殺菌。在其接種2重量份的乳酸菌並在38℃的溫度下培養10小時,並且對其進行冷凍乾燥來製備乳酸菌粉末。
此時,作為該乳酸菌,使用乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌、鼠李糖乳桿菌及乳酸雙歧桿菌雙微膠囊粉末,並且以相同的重量比混合上述六個種類來使用。
製備益生菌組合物
在100重量份的上述乳酸菌粉末混合250重量份的製備例3的猴頭菇提取物A、10重量份的維生素C、50重量份的低聚果糖、20重量份的無水結晶葡萄糖、10重量份的塔格糖、10重量份的酶改質甜菊糖
(Enzymatically Modified Stevia)、10重量份的漿果味粉末、100重量份的糊精、10重量份的二氧化矽來製備益生菌組合物。
本發明的實施例2
除了用猴頭菇提取物B代替猴頭菇提取物A外,以與實施例1相同的方法製備益生菌組合物。
本發明的實施例3
除了用猴頭菇提取物C代替猴頭菇提取物A外,以與實施例1相同的方法製備益生菌組合物。
本發明的實施例4
除了用香菇提取物粉末代替猴頭菇提取物A外,以與實施例1相同的方法製備益生菌組合物。
本發明的實施例5
除了用金針菇提取物粉末代替猴頭菇提取物A外,以與實施例1相同的方法製備益生菌組合物。
本發明的實施例6
除了未使用猴頭菇提取物A外,以與實施例1相同的方法製備益生菌組合物。即,在實施例6中,作為益生元,完全未使用蘑菇提取物。
本發明的實施例7
當製備乳酸菌粉末時,除了未使用乳酸雙歧桿菌雙微膠囊粉末外,以與實施例1相同的方法製備益生菌組合物。
本發明的實施例8
除了當製備乳酸菌粉末時未使用嗜酸乳桿菌CBG-C13(保藏編號:KACC 91980P)外,以與實施例1相同的方法製備益生菌組合物。
本發明的實施例9
除了當製備乳酸菌粉末時未使用鼠李糖乳桿菌CBG-C14(保藏編號:KACC 91981P)外,以與實施例1相同的方法製備益生菌組合物。
上文所述的本發明各種實施例,可在以下的實驗例中找到實
驗支持。以下實驗例是對本發明的進一步說明,而不是對本發明的限制。
本發明的實驗例1
以90名便秘的16歲至42歲的男女為對象,評價本發明的益生菌組合物的促進排便能力。此時,將實施例1至實施例9的益生菌組合物向各10名每日攝取兩次並記錄排便頻率。一次攝取量為60g。
並且,經過2個月後,與實驗前進行比較來評價排便次數的改善與否。其結果,確認到實施例1至實施例4的益生菌組合物對有便秘症狀的人具有優秀的改善便秘的能力。並且,實施例7及實施例8也呈現出具有改善便秘的能力,但是其根據個人稍有差異(表2)。
本發明的實驗例2
以36名經常腹痛或因腸道問題而經常腹瀉的18歲至43歲的男女為對象,評價本發明的益生菌組合物的腸道健康改善能力。此時,將實施例1至實施例9的益生菌組合物向各10名每日攝取兩次並記錄排便頻率。一次攝取量為60g。
並且,經過2個月後,與實驗前進行比較來評價腹瀉及腹痛次數的改善與否。本實驗例2的結果,呈現出實施例1至實施例3的具有
優秀的改善腸道健康的能力。此外,實施例7也呈現出具有改善腸道健康的能力,但是確認到對其未反應的人也相當多(表3)。
本發明的實驗例3
製備乳酸菌粉末
在100重量份的蒸餾水中,加入10重量份的牛奶並混合後進行殺菌。在其接種2重量份的乳酸菌並在38℃的溫度下培養10小時,並且對其進行冷凍乾燥來製備乳酸菌粉末。
此時,作為上述乳酸菌,以1:1的重量比混合上述表1的乳酸菌混合物和市面上銷售的乳酸菌混合物來使用。
即,使用表1的乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌、鼠李糖乳桿菌及乳酸雙歧桿菌雙微膠囊粉末,並且以相同的重量比混合上述六個種類來製備混合物。
並且,購入市面上銷售的乳酸乳球菌、屎腸球菌、糞腸球菌、嗜熱鏈球菌、兩岐雙岐桿菌、短雙歧桿菌、動物雙歧桿菌乳酸亞種、乾酪乳桿菌、加氏乳桿菌、德氏乳桿菌保加利亞亞種、瑞士乳桿菌、發酵乳桿
Claims (13)
- 一種益生菌組合物,其包含:乳酸菌粉末、蘑菇提取物及低聚果糖,其中該乳酸菌粉末包含選自於乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌所組成的一群組中的至少一者。
- 如申請專利範圍第1項所述之益生菌組合物,其中該益生菌組合物包含乳酸雙歧桿菌雙微膠囊粉末。
- 如申請專利範圍第1項所述之益生菌組合物,其中該嗜酸乳桿菌為嗜酸乳桿菌CBG-C13。
- 如申請專利範圍第1項所述之益生菌組合物,其中該鼠李糖乳桿菌為鼠李糖乳桿菌CBG-C14。
- 如申請專利範圍第1項所述之益生菌組合物,其中該乳酸菌粉末包含該乳酸雙歧桿菌的雙微膠囊粉末和該乳酸雙歧桿菌的非雙微膠囊,其中該乳酸雙歧桿菌的雙微膠囊粉末與該乳酸雙歧桿菌的非雙微膠囊的重量比為1:0.5至1.5。
- 如申請專利範圍第1項所述之益生菌組合物,其中該益生菌組合物具有便秘改善能力。
- 如申請專利範圍第1項所述之益生菌組合物,其中該益生菌組合物具有腹瀉及腹痛的改善能力。
- 如申請專利範圍第1項所述之益生菌組合物,其中該益生菌組合物有助於排便活動。
- 如申請專利範圍第1項所述之益生菌組合物,其中該蘑菇提取物為猴頭菇提取物。
- 如申請專利範圍第1項所述之益生菌組合物,其中該蘑菇 提取物為猴頭菇子實體的提取物。
- 如申請專利範圍第1項所述之益生菌組合物,其中該乳酸菌粉末還包含選自於乳酸乳球菌、屎腸球菌、糞腸球菌、嗜熱鏈球菌、兩岐雙岐桿菌、短雙歧桿菌,動物雙歧桿菌乳酸亞種、乾酪乳桿菌、加氏乳桿菌、德氏乳桿菌保加利亞亞種、瑞士乳桿菌、發酵乳桿菌、副乾酪乳桿菌、羅伊氏乳桿菌及唾液乳桿菌所組成的一群組中的至少一者。
- 一種益生菌組合物在製備改善便秘的藥物之用途,其中該益生菌組合物包含選自於乳酸菌粉末、蘑菇提取物及低聚果糖,該乳酸菌粉末包含選自由乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌所組成的一群組中的至少一者。
- 一種益生菌組合物在製備改善腹瀉及腹痛的藥物之用途,其中該益生菌組合物包含乳酸菌粉末、蘑菇提取物及低聚果糖,該乳酸菌粉末包含選自於乳酸雙歧桿菌、長雙歧桿菌、嗜酸乳桿菌、植物乳桿菌及鼠李糖乳桿菌所組成的一群組中的至少一者。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0124270 | 2016-09-27 | ||
KR1020160124270A KR101765559B1 (ko) | 2016-09-27 | 2016-09-27 | 노루궁뎅이버섯을 포함하는 프로바이오틱스 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201834673A true TW201834673A (zh) | 2018-10-01 |
Family
ID=59653804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106133484A TW201834673A (zh) | 2016-09-27 | 2017-09-27 | 包含猴頭菇的益生菌組合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11229672B2 (zh) |
KR (1) | KR101765559B1 (zh) |
CN (1) | CN111278300A (zh) |
TW (1) | TW201834673A (zh) |
WO (1) | WO2018062643A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109619540A (zh) * | 2019-02-22 | 2019-04-16 | 山东探克生物科技股份有限公司 | 一种具有润肠通便作用的益生菌组合物及其制备方法和应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102083067B1 (ko) | 2017-12-29 | 2020-04-28 | 산청기능성콩 영농조합법인 | 산채복합 추출물을 함유하는 항염증 활성이 있는 프리바이오틱스를 갖는 프로바이오틱스 조성물 및 이의 제조방법 |
KR102029263B1 (ko) | 2018-05-16 | 2019-11-08 | 주식회사 비피도 | 베타-엘-푸코피라노실-(1→3)-옥시-디-갈락토피라노오스를 포함하는 프리바이오틱스 조성물 |
CN109247570A (zh) * | 2018-10-25 | 2019-01-22 | 黑龙江惊哲森林农业科技开发有限责任公司 | 一种猴头菇胃动力酵素及其制备方法 |
KR102119133B1 (ko) | 2019-05-02 | 2020-06-26 | 선정완 | 유산균 분말 및 노니 분말을 포함하는 프로바이오틱스 조성물 |
CN111840336A (zh) * | 2020-07-15 | 2020-10-30 | 西安小天使生命营养科学健康研究院有限公司 | 益生菌水苏糖及其制备工艺 |
CN113456704B (zh) * | 2021-06-22 | 2023-04-07 | 四川省食用菌研究所 | 一种具有改善肠胃功效的药物组合物及其制备方法和应用 |
CN114832021A (zh) * | 2022-05-17 | 2022-08-02 | 比菲德(北京)生物科技有限公司 | 一种含有人体同源菌株的益生菌粉及其应用 |
CN115462532A (zh) * | 2022-07-28 | 2022-12-13 | 纽崔丝达食品科技(上海)有限公司 | 一种治疗妊娠呕吐的活性益生菌配方及其制备方法 |
CN115153030A (zh) * | 2022-09-08 | 2022-10-11 | 同芙集团(中国)股份有限公司 | 一种益生菌组合物及其应用、益生菌产品及其制备方法 |
EP4342481A1 (en) * | 2022-09-26 | 2024-03-27 | Hifas da Terra SL | Use of an extract of hericium erinaceus for the treatment of vaginal and cervical diseases |
CN116262125B (zh) * | 2023-01-19 | 2023-11-14 | 哈尔滨美华生物技术股份有限公司 | 保护胃黏膜、缓解胃炎的干酪乳杆菌l7-13及其应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1385970A4 (en) * | 2001-05-07 | 2004-11-24 | Biohub Co Ltd | PROCESS FOR THE PREPARATION OF LACTIC FERMENTATION SOLUTION BASED ON FUNGUS AND SOLUTION THUS OBTAINED |
KR20030070799A (ko) * | 2002-02-26 | 2003-09-02 | 주식회사 국순당 | 지방질, 다당류 및 단백질에 의하여 2중으로 미세캡슐화된유산균 제품의 제조방법 |
EP1384483A1 (en) * | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
KR100589113B1 (ko) * | 2002-12-31 | 2006-06-12 | 주식회사 바름인 | 대장암 원인 장내유해세균 효소 및 헬리코박터 파이로리성장 저해 활성을 갖는 버섯 유산균 발효물의 제조 및그의 용도 |
JP2005082517A (ja) | 2003-09-08 | 2005-03-31 | Asahi Denka Kogyo Kk | βグルカン・タンパク質複合組成物 |
US20100166721A1 (en) * | 2006-06-09 | 2010-07-01 | Fabiola Masri | Probotic compositions and uses thereof |
CN101579110A (zh) * | 2008-12-05 | 2009-11-18 | 王星丽 | 食用菌休闲食品 |
US9649380B2 (en) * | 2009-01-12 | 2017-05-16 | Pfizer Italia S.R.L. | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin |
JP5585769B2 (ja) * | 2009-05-15 | 2014-09-10 | ダイソー株式会社 | 腸管免疫賦活能を有する乳酸菌に対する効果促進剤 |
KR101266148B1 (ko) * | 2011-03-28 | 2013-05-21 | 재단법인 진안홍삼연구소 | 홍삼, 혼합유산균 및 올리고당류를 함유하는 조성물 및 건강기능식품 |
KR101274467B1 (ko) | 2011-08-10 | 2013-06-17 | (주)케비젠 | 유해세균에 대해 항균 활성을 갖는 락토바실러스 플란타룸 jbmi f5 균주 및 이의 용도 |
CN102919850B (zh) * | 2012-05-21 | 2016-04-20 | 孟令刚 | 一种用于营养食品及药品的组合物 |
EP2675173A1 (en) | 2012-06-15 | 2013-12-18 | Thomson Licensing | Method and apparatus for fusion of images |
JP6256335B2 (ja) | 2012-06-25 | 2018-01-10 | Jsr株式会社 | 固体撮像素子用光学フィルターおよびその用途 |
KR101401530B1 (ko) | 2012-07-06 | 2014-06-11 | (주)케비젠 | 공액리놀레산을 생산하는 비피도박테리움 롱검 균주 및 그 용도 |
KR101446309B1 (ko) | 2012-07-06 | 2014-10-07 | (주)케비젠 | 공액리놀레산을 생산하는 비피도박테리움 애니말리스 균주 및 그 용도 |
CN104719887A (zh) * | 2013-12-23 | 2015-06-24 | 无锡伟康生物科技有限公司 | 一种调节肠道菌群复合益生菌粉 |
CN104887647B (zh) * | 2014-03-08 | 2017-12-01 | 复旦大学 | 益生菌双层微胶囊及其制备方法 |
CN104544086B (zh) * | 2015-01-23 | 2016-10-05 | 广州小杉健康科技有限公司 | 一种可改善肠道菌群的保健食品及其制备方法 |
CN105901697A (zh) * | 2016-04-15 | 2016-08-31 | 邵素英 | 一种真菌提取物益生菌功能性食品 |
-
2016
- 2016-09-27 KR KR1020160124270A patent/KR101765559B1/ko active IP Right Grant
-
2017
- 2017-02-16 WO PCT/KR2017/001729 patent/WO2018062643A1/ko active Application Filing
- 2017-02-16 US US16/337,263 patent/US11229672B2/en active Active
- 2017-02-16 CN CN201780073282.XA patent/CN111278300A/zh active Pending
- 2017-09-27 TW TW106133484A patent/TW201834673A/zh unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109619540A (zh) * | 2019-02-22 | 2019-04-16 | 山东探克生物科技股份有限公司 | 一种具有润肠通便作用的益生菌组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2018062643A1 (ko) | 2018-04-05 |
US20200030395A1 (en) | 2020-01-30 |
KR101765559B1 (ko) | 2017-08-07 |
US11229672B2 (en) | 2022-01-25 |
CN111278300A (zh) | 2020-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201834673A (zh) | 包含猴頭菇的益生菌組合物 | |
Timmerman et al. | Monostrain, multistrain and multispecies probiotics—A comparison of functionality and efficacy | |
CN102089422B (zh) | 新的益生长双歧杆菌 | |
KR102146429B1 (ko) | 비피도박테리움 아니말리스 아종 아니말리스 균주 | |
CN109310719A (zh) | 益生菌的新医学应用 | |
CN106420847B (zh) | 辅助保护胃黏膜和/或缓解胃胀的组合物及其微生态制剂 | |
WO2017057718A1 (ja) | 難消化性成分を含む飲食品および大腸内水素ガス産生剤 | |
BRPI0615785B1 (pt) | Composição inibidora da absorção de colesterol compreendendo bactérias do gênero bifidobacterium | |
US20230104564A1 (en) | Culture process for enhancing proliferation of lactic acid bacteria by using red ginseng | |
TWI785815B (zh) | 用於促進益生菌生長的方法 | |
CN107647251A (zh) | 一种复合食用菌营养咀嚼片的制备方法 | |
JP2021524751A (ja) | 組成物及びその使用 | |
TW202308670A (zh) | 使用包含乳酸桿菌屬菌株和韓藥材的組合施用療法的抗老化組合物 | |
CN109846984A (zh) | 一种具有治疗慢性胃炎功能的多组分复合的益生菌 | |
Baek et al. | Probiotics and prebiotics as bioactive components in dairy products | |
KR100411198B1 (ko) | 암 세포주 증식 억제제 | |
KR101193602B1 (ko) | 쑥을 탄소원으로 생육가능한 미생물 및 그 용도 | |
WO2008075685A1 (ja) | IgA産生促進剤 | |
US20220192246A1 (en) | Composition and method for synbiotics supplement containing probiotics, digestive enzymes, prebiotics, yeast, protein, b vitamins, and flavoring agent | |
Jung et al. | Synergistic antimicrobial effect of Achyranthes japonica Nakai extracts and Bifidobacterium supernatants against Clostridium difficile | |
KR100611720B1 (ko) | 비피도박테리움 인팬티스 Maeil-K9 유래의 세포성분함유 추출물 및 이를 함유하는 위암 및 대장암의 예방용및 치료용 조성물 | |
Ibrahim et al. | Dietary modulation of gut microbiota by cultured products | |
KR102366898B1 (ko) | 천연 추출물과 프로바이오틱스를 포함하여 위와 장 건강에 도움을 주는 조성물 | |
Starovoitova et al. | Probiotic strains with hypocholesterolemic activity as potential basis of functional food products for prevention and concomitant treatment of pathological conditions associated with high cholesterol levels | |
CN115960737A (zh) | 用于促进益生菌生长的方法 |